Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**AstraZeneca Pharma India Limited – Financial Risk Summary** AstraZeneca's largest financial exposure stems from compliance risk (10.0/10 score) with estimated remediation costs of ₹3–10 crore, compounded by unknown Extended Producer Responsibility (EPR) applicability in pharmaceuticals, creating contingent liability uncertainty. Under SEBI BRSR Core Expansion mandates, non-compliance with environmental disclosures and carbon accounting obligations risks enforcement action and potential delisting for listed entities, directly threatening market valuation. The company's failure to report Scope 1 and 2 emissions despite ₹1716.3 crore revenue triggers immediate disclosure gaps under BRSR P6; if EPR is determined applicable, additional collection and recycling infrastructure costs could add ₹2–5 crore annually. Urgent priority: formalize GHG accounting, clarify EPR regulatory status, and establish compliance roadmap to mitigate regulatory penalties and investor confidence erosion.
Source: AstraZeneca Pharma India Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.